CVS Caremark reaches FTC settlement ending PBM, pharmacy investigations

CVS Health reached a global settlement with the FTC, ending litigation and investigations tied to its PBM and affiliated pharmacy operations.

• Deal targets rebate practices, pharmacy network contracting, spread pricing, and vertical integration concerns flagged by regulators.
• Commercial client offerings will shift toward net-cost member cost sharing, point-of-sale rebate passthrough, reduced rebate guarantees, and enhanced pricing disclosures.
• Settlement includes an insulin out-of-pocket cap of USD 25 per month for members under a new offering.